Al B. Benson III, MD, FACP, FACCC, FASCO

Articles

Future Outlooks in the Treatment of Metastatic Colorectal Cancer

August 1st 2024

Experts discuss their vision for the future of colorectal cancer treatment and anticipated advancements in the field.

Additional Key Takeaways of ASCO 2024 Data in mCR

August 1st 2024

The panel of leading oncologists summarize crucial updates and key insights on colorectal cancer from the ASCO 2024 conference.

Examining the Evolving 3L Treatment Landscape for mCRC

July 24th 2024

Colorectal cancer specialists examine treatment sequencing strategies for third-line and subsequent therapy settings, while also evaluating regorafenib's efficacy and real-world outcomes.

Fruquintinib for mCRC: Data from the FRESCO & FRESCO-2 Studies

July 24th 2024

Oncology experts evaluate the influence of fruquintinib on current treatment protocols, drawing insights from the FRESCO and FRESCO-2 clinical studies.

Exploring Data Outcomes From the SUNLIGHT Trial

July 17th 2024

Leading colorectal cancer specialists analyze the SUNLIGHT trial results, focusing on age-related efficacy data and its implications for treatment strategies.

Factors Driving 3L Therapeutic Selection for mCRC

July 17th 2024

Key opinion leaders explore treatment selection for third-line metastatic colorectal cancer patients, examining factors influencing therapy choice with particular focus on comparing fruquintinib to TAS-102 (with or without bevacizumab).

Existing Challenges for Patients Receiving 3L+ Therapies in mCRC

July 10th 2024

The colorectal cancer experts offer insights on a patient case and investigate the obstacles faced by patients with metastatic colorectal cancer requiring third-line or later therapy.

Exploring Toxicities for Second Line Treatments in mCRC

July 10th 2024

The panel examines prevalent adverse events experienced by patients receiving second-line biomarker-directed therapy for metastatic colorectal cancer.

Novel Combination Regimens for 2L mCRC: Insights from ASCO 202

July 3rd 2024

The panel examines data from the ZL-IRIAN study and Phase II study, which provide insights into second-line treatment options for patients with metastatic colorectal cancer.

Clinical Considerations for 2L Treatment Sequencing in mCRC

June 26th 2024

Key opinion leaders outline their strategies for sequencing second-line treatments in chemotherapy-refractory metastatic colorectal cancer patients, considering the influence of previous therapies on their decision-making process.

Overview of Molecular Testing and Barriers in mCRC

June 26th 2024

The panel of CRC experts explores the significance of molecular testing for mCRC patients, emphasizing recommended biomarkers and optimal testing timelines.